Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges ...

Jan 20 (Reuters) - Novavax said on Tuesday it was entering into a licensing agreement with Pfizer for a substance that helps ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally ...

Robert F. Kennedy’s position on vaccines is profoundly "anti-science" and making progress would require a new health secretary, Pfizer Chief Executive Albert Bourla said Wednesday. “I have very ...

By Yadarisa Shabong Jan 20 (Reuters) - Britain's GSK and Japan's Shionogi said on Tuesday that Pfizer will exit their HIV ...

“Stories of Hope” shares the stories of the people and scientists at the forefront of advancing medical science and pushing ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Pfizer is one of the world's largest pharmaceutical companies. Even after losing more than half of its value, it still has a ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

All three of these stocks sport dividend yields above 6%.